Cybin Inc. Common Stock
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Cybin Inc. (Ticker: HELP) is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. The company advances a pipeline of novel psychedelic derivative drug candidates, including CYB003, a deuterated psilocybin analog for major depressive disorder; CYB004, a deuterated DMT analog for generalized anxiety disorder; and CYB005, a phenethylamine derivative for neuroinflammation-related conditions; along with preclinical programs targeting additional central nervous system disorders. Cybin operates globally with clinical trials conducted in North America, Europe, and Australia, targeting patients suffering from treatment-resistant depression, anxiety, and other neuropsychiatric conditions. Founded in 2019 and headquartered in Cambridge, Massachusetts, with additional facilities in the United Kingdom and Canada, the company recently completed a strategic name change from Cybin Inc. Common Stock (previously CYBN) to its current ticker HELP in late 2025, reflecting a rebranding to emphasize its mission of providing help through innovative mental health treatments; this followed a major Series A funding round exceeding $130 million to support Phase 3 trials of CYB003 and expanded preclinical development, as well as a key partnership with a leading contract research organization for global trial execution announced in mid-2025.
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
Helus Pharma: APPROACHing Inflection: Pivotal Readout Sets Up Asymmetric Upside
Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
Cybin: A Speculative Bet On Their Pivotal Depression Readout
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering
Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering
Helus Pharma™ Announces US$50 Million Underwritten Offering
Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress
Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference
Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York
CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference
Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan
Cybin: Regulatory Tailwinds Unlock Asymmetric Upside (Rating Upgrade)
How Trump's psychedelics executive order could unlock stalled cannabis reform
Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions
Helus Pharma Announces Chief Executive Officer Transition; Eric So to Resume Role as Interim Chief Executive Officer
Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs